Head-to-head · WeighScore
Andrew Meds vs Bon Health
By GLP-1 ScorecardUpdated
Score comparison
Bon Health has the higher recorded score — 69.7/100 to 67.1/100.
Bon Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bon Health shows both the monthly equivalent and the amount billed for each plan length. Ask what happens to unused prepaid money if you stop early.
Before you choose
Before comparing the headline prices, the Andrew Meds review and the Bon Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Andrew Meds vs Breeze Meds and Bon Health vs CoreAge Rx compare each of them with another graded program, and the list of alternatives to Andrew Meds ranks the programs closest to Andrew Meds on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the PlexusDx review covers one graded close to these two, at 67.7/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Andrew Meds | Bon Health |
|---|---|---|
| WeighScore | 67.1/100 | 69.7/100 |
| Grade | C | C |
| Site position | #182 | #128 |
| Semaglutide | $199/mo (standard compounded plan; $149/mo figure on a 12-month plan) | $220/mo advertised on monthly billing; $1,140 billed yearly at the $95/mo equivalent |
| Tirzepatide | $299/mo (standard compounded plan; $229/mo figure on a 12-month plan) | $285/mo advertised on monthly billing; $1,620 billed yearly at the $135/mo equivalent |
| Coverage | 50 states and D.C. advertised; medication availability varies | Confirm eligibility for the selected treatment |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Lists separate prices for both injections and both plan options
- Names the independent medical group and three pharmacy partners
- Describes billing at the start of each plan cycle
What to consider
- Twelve-month figures do not establish the selected debit schedule or early-exit cost
- The FAQ says refund requests are handled case by case
- Confirm your dispensing pharmacy and medication availability
Strengths
- Product pages show separate monthly, quarterly, six-month and annual totals
- Product pages advertise no membership fee
- The site identifies its merchant of record
What to consider
- The lowest monthly equivalents require annual billing
- The public site terms do not settle the refund on an unused prepaid balance
- Confirm the assigned pharmacy and selected invoice before paying
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.